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ABSTRACT
Low plasma busulfan (Bu) area under the concentration-time curve (AUC) is associated with graft failure and
relapsed leukemias, and high AUC with toxicities when Bu is used orally or i.v. 4 times daily combined with
cyclophosphamide in myeloablative hematopoietic stem cell transplantation (SCT) conditioning regimens.
We report Bu AUC and its association with clinical outcomes in 130 patients with hematologic malignancies
given a once-daily i.v. Bu (3.2 mg/kg days25 to22) and fludarabine (Flu, 50 mg/m2 days26 to –2) regimen. To-
tal-body irradiation (TBI) 200 cGy  2 was added for 51 patients with acute leukemias. Plasma AUC varied
3.6-fold (2184-7794 mM$min, median 4699 mM$min). Patients with an AUC .6000 mM$min had lower overall
survival (OS) than those with AUC#6000 mM$min at 12 months (38% versus 74%) and 36 months (23% versus
68%, P\ .001). This effect was apparent in patients with standard-risk and high-risk disease, and persisted when
potential confounders were considered (hazard ratio 3.2, 95% confidence interval 1.7-6.3). Nonrelapsemortality
(NRM) at 100 days (6% versus 19%) and progression free survival (PFS; 58% versus 16%) at 3 years were better
with AUC#6000 mM$min. These data support a role for therapeutic dose monitoring and dose adjustment with
daily i.v. busulfan.
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Busulfan (Bu) is a bifunctional DNA alkylating
agent important in conditioning regimens for hemato-
poietic stem cell transplantation. Plasma area under
the concentration-time curve (AUC) after oral Bu
varies about 10-fold because of nausea and vomiting,
unpredictable and variable intestinal absorption, and
individual differences in hepatic metabolism [1-3].
Furthermore, Bu levels are known to vary with age,
disease status, obesity (unless dosing is based on
body surface area or adjusted ideal body weight) and,
in children, with circadian rhythmicity [2,4,5]. When
given in 4 oral doses daily with cyclophosphamide220(Cy) in Bu/Cy, low plasma Bu exposure has been asso-
ciated with potentially fatal outcomes including graft
failure and relapse of chronic myelogenous leukemia
(CML), whereas high exposure is associated with tox-
icities including veno-occlusive disease of the liver
(VOD, a.k.a. sinusoidal obstruction syndrome, SOS)
and neurotoxicity [1,6-10]. Targeting Bu levels after
oral dosing is associated with successful engraftment
and favorable outcomes [11-13].
An intravenous formulation was developed to
improve dose assurance, with decreased variability in
plasma AUC; however, a severalfold range in AUC
remains between patients [14-17]. We are using
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designed to be convenient, allow consistent dose-to-
dose Bu levels in the same patient and complete drug
clearance between doses, and minimize toxicities [18-
20]. This regimen combines 2 effective antineoplastic
drugs that may act synergistically through multiple
enzymes including Flu inhibition of DNA ligase and
DNA primase, and prevention of DNA polymeriza-
tion, to reduce repair of alkylator-induced damage
[19]. We have previously reported the outcomes with
this regimen in a variety of hematologic malignancies
[20], demonstrating relatively low toxicities and nonre-
lapse mortality (NRM) compared to outcomes re-
ported with Bu/Cy [21-24]. However, the need for
therapeutic drug monitoring and the optimal Bu expo-
sure when given once daily i.v. with Flu is unknown.
Here, we report Bu exposure by AUC after once-daily
i.v. dosing and associations between Bu exposure and
clinical outcomes.
MATERIALS AND METHODS
Patients
Adult patients undergoing allogeneic stem cell
transplantation (SCT) conditioning for hematologic
disease at a single center between July 2000 and Octo-
ber 2005 were enrolled if they provided informed con-
sent for the study and met institutional guidelines for
transplant eligibility. The protocol and consent forms
were approved by the University of Calgary Health
Research Ethics Board.
Patients were considered standard risk if trans-
planted during first or second complete remission
(CR) of acute leukemia or first chronic phase (CP) of
CML; all other patients were high risk.High-resolution
human leukocyte antigen (HLA) typing was completed
in all patients and donors forDRandDQ;Class I typing
was done at medium resolution for A, B, and C until
2001, and thereafter all typing was high resolution.
Treatment Regimen
Patients received i.v. Bu (Busulfex, PDL Bio-
pharma, Redwood City, CA) at a myeloablative dose
of 3.2 mg/kg on days –5 to –2 and Flu 50 mg/m2 on
days –6 to –2 before SCT. Busulfan doses were given
over 3 hours, and were based on actual body weight
unless the patient was $25% above ideal body weight
(IBW, 50 kg [men] or 45.5 kg [women] 1 2.3 mg/kg
for each inch over 5 feet), in which case adjusted ideal
body weight was used (ideal body weight1 0.4[actual –
ideal body weight]). Additional total-body irradiation
(TBI) 200 cGy  2 doses was given to 51 patients
with acute leukemias on day –1 or 0. Seizure prophy-
laxis with phenytoin started 7 days before the first
dose of Bu until 24 hours after the last dose to maintain
trough levels of 40-80 mmol/L.Graft-versus-host disease (GVHD) prophylaxis
comprised short-course intravenous methotrexate
(MTX) 15 mg/m2 on day 1 and 10 mg/m2 on days 3,
6, and 11, and cyclosporine A 2.5 mg/kg i.v. or 6.25
mg/kg orally twice a day titrated to a trough level of
150-400 mg/L. MTX doses were decreased according
to standardized pharmacy guidelines for renal failure
or severe mucositis, and folinic acid 5 mg was given ev-
ery 6 hours from 24 hours after each MTX dose until
12 hours before the next dose. Rabbit antithymocyte
globulin (ATG; Thymoglobulin, Genzyme, Cam-
bridge, MA) 4.5 mg/kg was given in divided doses to
all patients on days 22, 21, and 0 before transplant.
Acute GVHD (aGVHD) and chronic GVHD
(cGVHD) were graded according to standard criteria
[25] and treated by immunosuppression with steroids,
ATG,mycophenylate mofetil (MMF), monoclonal an-
tibodies (mAbs), calcineurin inhibitors, and/or photo-
pheresis as clinically indicated.
Standard antiinfective prophylaxis with acyclovir
and trimethoprim/sulfamethoxazole was given for at
least 1 year posttransplant, and routine antifungal
prophylaxis was not given. Growth factors were not
routinely given. All blood products were from cyto-
megalovirus (CMV) antibody negative donors, and
pp65 antigen surveillance was instituted to allow pre-
emptive therapy with gancyclovir for CMV reactiva-
tion.
Busulfan Plasma AUC Determination
For the pharmacokinetic analysis patient blood
samples (5 mL) were collected in heparinized tubes
after the third Bu dose (on day –3), at the end of infu-
sion and at 1, 3, 5, and 7 hours post-Bu infusion.Day –5
pharmacokinetics were also done on 8 consecutive
consenting patients to ensure consistency between
doses in AUC. Bu concentrations in plasma were
determined by UV-HPLC as previously described,
with slight modifications [26]. The modifications
were mainly done in the Bu derivatization procedure,
which was performed with 0.5 mL of 15% sodium
diethyldithiocarbamate trihydrate (DDTC) in 0.1
N sodium hydroxide solution subsequently extracted
with 1/3 volume of chloroform. Prior to the derivatiza-
tion step, 0.5-mL plasma samples were deproteinized
by an equal volume of acetonitrile. Derivatized Bu
was extracted with 2.0 mL of ethyl acetate, followed
by evaporation under nitrogen and reconstitution in
100 mL of methanol; 30 mL was injected into the
HPLC system (Agilent 1100, Agilent Technologies,
Santa Clara, CA). The analysis was performed on
a Waters NovaPak C18 (4 mm; 4.6  250 mm) analytic
column using 80%methanol mobile phase delivered at
1.5 mL/min. Plasma drug concentration was measured
at 278 nmby a diode array detector. Intraday and inter-
day coefficient of variation for the assay were\15%,
222 M. Geddes et al.limit of quantification was 0.05 mg/mL, and the assay
was linear between 0.05 and 5.0 mg/mL.
Pharmacokinetic data were analyzed by noncom-
partmental analysis using WinNonlin Professional
version 5.0.1 software (Pharsight Corp., Mountain
View, CA). The AUC was calculated by the log-linear
trapezoidal rule from time zero to the last sampling
time (AUClast). The AUC from the last sampling
time to infinity was extrapolated by Clast/lz, where
Clast and lz are the last measured (nonzero) plasma
Bu concentration and the terminal slope on the Ln
scale, respectively, and this extrapolated area was
added to the AUClast for the final AUC to infinity cal-
culation (AUCN). The fraction of the AUCN extrapo-
lated from Clast/lz was\10% of the total AUC value
for all patients.
Engraftment
Engraftment was assessed by daily complete blood
counts until discharge, then at least weekly until bone
marrow aspiration and biopsy at 12 weeks (sooner if
clinically indicated). Neutrophil engraftment was de-
fined as the first of 3 consecutive days that neutrophils
were $0.5  109/L, and platelet engraftment as the
first day after platelets remained $20  109/L for 7
days without transfusion support. If engraftment did
not occur by 28 days in the absence of residual marrow
malignancy, the patient was deemed to have primary
graft failure. Chimerism for all patients was assessed
by DNA analysis of variable number of tandem repeats
by PCR or, in sex-mismatched donor-recipient pairs,
through FISH studies for the X and Y chromosomes.
Toxicity
Mucositis was graded according to the Bearman
scale and veno-occlusive disease (VOD) by the Jones
criteria [27,28]. Alanine aminotransferase and conju-
gated bilirubin were monitored twice weekly during
the first 4 weeks and maximum weekly measurements
were recorded. Hemorrhagic cystitis was defined as
macroscopic hematuria with pain on voiding. Patients
were monitored for seizure activity and evidence of
microangiopathic hemolytic anemia.
Statistical Analysis
A threshold value of 6000 mM$min was chosen to
evaluate toxicities and outcomes with once-daily i.v.
Bu. This was extrapolated from previously reported
data by multiplying times 4 the AUC previously asso-
ciated with decreased survival using a 4 times daily i.v.
BuCy regimen for CML (AUC .1520 mM$min) to
approximate the equivalent total daily Bu exposure
[15]. We also evaluated patient subgroups with differ-
ent ranges of Bu exposure for NRM; this ranged be-
tween 9% and 23% in groups with exposures of 2000
to 6000 mM$min. Mortality in the group exposed to5500-6000 mM$min (N 5 11) was 9% compared to
58% for the 16 patients with exposures .6000
mM$min (P 5 .03), despite a higher proportion of pa-
tients with high-risk disease in the lower exposure
group (91% versus 62.5%). Above this level the differ-
ence between those above and below the threshold
diminished as more patients with NRM moved below
the threshold; therefore, use of a 6000 mM$min thresh-
old allows a greater margin of safety and is biologically
consistent with previous data.
NRM, engraftment, and overall survival (OS) were
also assessed in patients with a daily Bu exposure of
\3500 mM$min daily, approximately 4 times the
AUC previously associated with decreased engraft-
ment using 4 times daily oral Bu/Cy (AUC \900
mM$min), and the group with an intermediate AUC
3500-6000 mM$min [7,8].
Patient and disease characteristics and treatment
toxicities were compared between patients with high
(.6000 mM$min) and low (#6000 mM$min) Bu expo-
sure. Kaplan-Meier curves were constructed to exam-
ine OS and progression-free survival (PFS) and the
log-rank test compared equality of the survivor func-
tions by Bu exposure. Patients known to be alive (for
OS) and relapse-free (for PFS) were censored on the
last day of follow-up. Cox proportional hazards mod-
eling was used to examine the individual impact of
potential confounding variables on the crude hazard
ratio for death from any cause with high versus low
Bu exposure. These included age, CD341 cell dose,
high-risk or standard-risk disease status, use of TBI,
stem cell source, matched related or alternative donor
type, CMV positivity in donor or recipient, $1 HLA
mismatch, ABO compatibility, and female donors
withmale recipients.We also estimated the cumulative
incidence in the presence of competing risks of nonre-
lapse mortality (NRM), relapse, Grade II-IV or III-IV
aGVHD and cGVHD.
RESULTS
One hundred thirty patients with a variety of he-
matologic conditions were enrolled. One hundred
fourteen patients (88%) had low Bu exposure (AUC
#6000 mM$min), whereas 16 (12%) had high exposure
(AUC .6000 mM$min). Follow-up among survivors
ranged from 4-67 months (median 29 months), and
was shorter among those with low Bu exposure
(median 28 months) compared to high Bu exposure
(median 39 months). Patient, disease, and transplant
characteristics by Bu exposure are shown in Table 1.
Busulfan Pharmacokinetics
Busulfan AUC ranged from 2184-7794 mM$min
(mean 4716, median 4699 mM$min, Figure 1). The
mean clearance was 13.1 6 4.0 L/h, with a percent
coefficient of variation of 30% as the measure of
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i.v. busulfan pharmacokinetics, 8 patients were evalu-
ated by collection of samples on days 1 and 3 of busul-
fan administration (transplant days 25 and 23). PK
Table 1. Patient, Disease and Treatment Characteristics of Patient
Groups According to Busulfan Exposure
Characteristic
AUC
\6000 mM$min
(n 5 114)
AUC
.6000 mM$min
(n 5 16)
Age (years)
range 19-66 21-63
mean (standard
deviation)
43.6 (11.6) 42.9 (13.3)
Diagnosis (%)
AML 43 (37.7) 9 (56.3)
MDS 6 (5.3) 1 (6.3)
ALL 16 (14.0) 1 (6.3)
CML 13 (11.4) 1 (6.3)
CLL 7 (6.1) 0 (0.0)
Hodgkins lymphoma 3 (2.6) 1 (6.3)
NHL 15 (13.2) 1 (6.3)
Multiple myeloma 6 (5.3) 2 (12.5)
Other 4 (3.5) 0 (0.0)
Donor type (%)
Matched related 67 (58.8) 6 (37.5)
Alternative donor 47 (41.2) 10 (62.5)
Disease status (%)
Standard risk 52 (45.6) 9 (56.3)
High risk 62 (54.4) 7 (43.8)
TBI (%) 45 (39.4) 6 (37.5)
Stem cell source (%)
Bone marrow 96 (84.2) 14 (87.5)
Peripheral blood 18 (15.8) 2 (12.5)
CD341 cells  106/kg
Range 0.4-16.7 1.2-13.3
Median 5.0 5.6
Female donor to male
recipient (%)
31 (27.2) 1 (6.3)
CMV 1 donor or
recipient (%)
82 (71.7) 9 (56.3)
AML indicates acute myelogenous leukemia; MDS, myelodysplastic
syndrome; ALL, acute lymphoblastic leukemia; CML, chronic
myelogenous leukemia; CLL, chronic lymphocytic leukemia;
NHL, non-Hodgkins lymphoma.
Figure 1.Distribution of plasma busulfan AUC values after 3.2 mg/
kg once-daily i.v. dosing.parameters on each day were calculated by noncom-
partmental analysis and exposure was not significantly
different between days 1 and 3 for each patient, consis-
tent with previous studies done by our group and
others [18,20]. Comparison between noncompart-
mental analysis and 1 and 2 compartment models did
not show any significant differences in calculated
AUCs.
Engraftment
There was no difference between groups with an
AUC #6000 versus .6000 mM$min in median num-
ber of days to stable neutrophil engraftment (15 days,
range: 10-115 days versus 14.5 days, range: 11-19
days, P 5 .38 by Wilcoxon rank-sum) and platelet en-
graftment (18 days, range: 0-115 days versus median
18 days, range: 0-25 days, P 5 .36). Graft failure was
seen in 3 patients, all with an AUC #6000 mM$min
(P 5 .51); AUC values in these patients were 5124
mM$min, 2639 mM$min, and 4384 mM$min.
Regimen-Related Toxicities
No difference in organ-specific toxicities was seen
between groups, including seizures, hemolytic anemia,
or hemorrhagic cystitis, and no diffuse alveolar hemor-
rhage was seen (Table 2). Although not statistically
significant, there was a trend to less severe mucositis
in the low exposure group (P 5 .08); all patients with
Bearman grade I mucositis had an AUC \6000
mM$min. No patient had clinical evidence of VOD,
and when weekly maximum bilirubin (total and conju-
gated) and alanine aminotransferase levels were com-
pared between exposure groups in the first 4 weeks
after transplant, no difference was seen.
GVHD
The total incidence of aGVHD and cGVHD was
not different between groups. The cumulative inci-
dence at 3 months of grade III-IV aGVHDwas similar
at 25% in the group with high exposure (95% confi-
dence interval [CI]: 8%-47%) and 13% in the lower ex-
posure group (95%CI: 8%-20%).Grade II-IVGVHD
Table 2. Incidence of Organ-Specific Toxicities Seen in Patient Groups
According to Busulfan Exposure
AUC
\6000 mM/min,
median (%)
n 5 114
AUC
.6000 mM/min,
median (%)
n 5 16 P
Stomatitis grade 2-3a 96 (84) 16 (100) .08
Hemorrhagic cystitis 15 (13) 3 (19) .54
Microangiopathic
Hemolytic anemia
6 (5) 0 (0) .35
Seizures 2 (2) 1 (6) .26
All tests were grouped tests of proportions (chi-square).
aBearman scale [25].
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ulation with Bu AUC #6000 mM$min and 5 of 16
(31%) of our sample with Bu AUC .6000 mM$min.
The cumulative incidence of cGVHD at 8 months for
patients with high and low busulfan exposure was sim-
ilar at 50% (95% CI: 24%-71%) and 52% (95% CI:
42%-60%), respectively.
Relapse
The cumulative incidence of relapse is shown in
Figure 2. The relapse rate at 12 months was not differ-
ent between groups at 31% (95% CI: 11%-54%)
among those with high Bu exposure compared to
20% (95% CI: 13%-28%) among those with low Bu
exposure.
NRM
There was a lower cumulative incidence of NRM
in the low Bu exposure group (P 5 .002); at 100 days
NRM was 6% (95% CI: 3%-12%) compared to 19%
in the high exposure group (95% CI: 5%-40%; Fig-
ure 3). At 12 months, the cumulative incidence of
NRM remained higher in the group with busulfan
AUC .6000 mM$min (38%, 95% CI: 15%-60%)
compared to those with AUC #6000 mM$min (14%,
95% CI: 9%-22%). Causes of NRM in the 2 groups
are outlined in Table 3. Deaths were considered to
be from GVHD if they were a direct result of
GVHDor a complication of GVHD therapy (ie, infec-
tion). They were considered to be from sepsis if they
were a result of infection in the absence of aGVHD
or chronic extensive GVHD and its treatment.
OS and PFS
Estimated survival of the entire group was 70% at
12 months (95% CI: 61%-77%) and 62% at 36
months (95% CI: 52%-70%). Patients with an AUC
.6000 mM$min had worse OS than those in the low
Figure 2. Cumulative incidence of relapse among allogeneic hema-
topoietic SCT recipients according to busulfan exposure as mea-
sured by AUC.exposure group (P \.001; Figure 4). At 12 months,
survival in the group with AUC #6000 mM$min was
74% (95% CI: 65%-82%) compared to 38% (95%
CI: 15%-60%) in the group with high Bu exposure,
and at 36 months, survival in these groups was 68%
(95% CI: 57%-76%) compared to 23% (95% CI:
6%-46%), respectively. The survival difference was
most striking in standard risk patients (P \ .001),
with a 3-year estimated OS of 79% (95% CI: 64%-
89%) in the low exposure group and 33% (95% CI:
8%-62%) in the high Bu exposure group. The effect
was also seen among patients with high-risk disease
(P5 .05), although the number of events in this group
was small; 3-year estimated survival in the low expo-
sure group was 59% (95% CI: 45%-71%) compared
to 14% (96% CI 1%-46%) in the high Bu exposure
group.
Earlier censoring of patients in the low Bu expo-
sure group because of shorter time under observation
may complicate this comparison; therefore, we also
generated conservative Kaplan-Meier curves (not
shown) under the assumption that all censored individ-
uals in the low exposure group died on the last day of
follow-up. Estimated OS at 12 months remained sig-
nificantly lower among patients in the high exposure
group (38%, 95%CI: 15%-60%) compared with those
in the low exposure group (61%, 95% CI: 52%-70%).
PFS at 3 years estimated by Kaplan-Meier curves
was higher in the group with Bu exposure #6000
mM$min (P\ .001) at 58% (95%CI: 47%-67%) com-
pared to 16% in those with high busulfan exposure
(95% CI: 3%-38%; Figure 5). When the conservative
analysis done above was repeated for PFS, it remained
significantly worse among patients with high versus
low exposure.
In a Cox proportional hazards model, the crude
hazard ratio for the effect of high busulfan exposure
Figure 3.Cumulative incidence of nonrelapsemortality among allo-
geneic hematopoietic cell transplant recipients according to busulfan
exposure as measured by AUC.
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Timing
Cause of Nonrelapse
Mortality
Number of Deaths
AUC #6000 mM/min, n 5 114 (%)
Number of Deaths AUC .6000
mM/min, n 5 16 (%)
\100 days
posttransplant
Sepsis/infection 2 (2) 1 (6)
GVHD 3 (3) 2 (13)
2 GVHD/infection 1 GVHD
1 GVHD/PTLD 1 GVHD/infection
Other 2 (2) 0 (0)
1 encephalopathy, 1 arrhythmia
100 days or more
posttransplant
Sepsis/infection 1 (1) 0 (0)
GVHD 4 (4) 3 (19)
1 GVHD 1 GVHD
2 GVHD/infection 2 GVHD/infection
1 GVHD/PTLD
Other 3 (3) 1 (6)
2 graft failure, 1 IPS 1 intracerebral hemmorhage
1 adenocarcinoma, 1 spont liver
hemorrhage
Total 17 (15) 7 (44)
GVHD indicates graft-versus-host disease; PTLD, posttransplant lymphoproliferative disorder; IPS, interstitial pneumonia syndrome.(AUC .6000 mM$min versus#6000 mM$min) on OS
was 3.2 (95% CI: 1.7%-6.3%). Simultaneous adjust-
ment for all possible confounders was not possible be-
cause of the relatively small number of events, but we
did explore the impact on the hazard ratio of adjust-
ment for 1 variable at a time. Adjustment for age,
CD341 cell dose, standard versus high-risk disease
group, treatment with TBI, stem cell source, donor
type, ABO incompatibility, the presence of at least 1
HLA mismatch and female donor-to-male recipient
did not alter the crude hazard ratio appreciably (data
not shown). Adjustment for CMV positivity in either
donor or recipient increased the estimated hazard ratio
of high Bu exposure to 4.1 (95% CI: 2.0%-8.1%).
We also analyzed any differences in engraftment
and OS between patients with AUC\3500 mM$min,
Figure 4.OS of allogeneic hematopoietic SCT recipients according
to busulfan exposure group as measured by AUC.and between 3500 and 6000 mM$min. No difference
was seen in days to stable neutrophil or platelet en-
graftment or OS between groups (data not shown).
DISCUSSION
Although the 3.6-fold variability in Bu AUC fol-
lowing once-daily i.v. dosing with Flu is less than
that seen with oral Bu, this is the first study showing
decreased OS and PFS, and increased NRM, among
patients with Bu exposures greater than an AUC of
6000 mM$min. It was hoped that an i.v. form of Bu
might allow safe administration without the need for
TDM, which is often used with oral 4-times daily
BuCy to keep Bu exposure within an AUC range of
900-1500 mM$min, a range that has been associated
Figure 5. PFS of allogeneic hematopoietic SCT recipients accord-
ing to busulfan exposure as measured by AUC.
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daily i.v. BuCy2 regimen for CML [15]. High exposure
to once-daily i.v. Bu given with Cy is likely to also be
associated with higher toxicity. Although substitution
of Flu for Cymight have been expected to allow higher
exposures to Bu, our data support a threshold effect
with high busulfan exposure associated with an in-
creased risk for lethal adverse events. Although this
high NRM could be attributable to drug exposure, it
is also possible that the high exposure is a surrogate
marker for metabolic factors contributing to both
high exposure and to other factors leading to a higher
risk of NRM. We may answer this in time if mortality
in patients who would otherwise have been overex-
posed remains high despite having exposure adjusted
on the basis of a test or day 1 dose.
The reason for better survival in patients with a Bu
AUC #6000 mM$min appears to be reflected in the
nonrelapse mortality. The small number of patients
with adverse events in the high Bu exposure group
limits the ability to determine the specific cause of
increased mortality; specific toxicities were not signif-
icantly different between Bu exposure groups, how-
ever, this study is not powered to detect them. One
way in which more intense conditioning may increase
NRM is by increasing tissue damage and inflamma-
tion, possibly stimulating GVHD; this effect has
been suggested previously with i.v. busulfan in Bu/
Cy [14,29]. The finding of no difference in aGVHD
and cGVHD rates between AUC groups is consistent
with that seen in previous case series [9]; however,
most of the deaths in our high Bu exposure patients
were related to GVHD or complications of its treat-
ment, that is, infections. The worse survival of patients
with high Bu exposure was most striking in patients
with low-risk disease, a group expected to do well.
Our data suggest that avoiding exposures to Bu
AUC .6000 mM$min may be associated with reduc-
tion of the already low NRM in this group. Because
of the marked differences in outcomes between groups
with high and low busulfan exposure we did not feel it
was ethically justified to continue accruing patients to
this study.
Patient baseline characteristics were assessed and,
although some differences existed, in multiple bivari-
ate analyses none except for CMV positivity in donor
or recipient were found to have a meaningful impact
on the hazard ratio for death associated with high Bu
exposure. As more patients in the low Bu exposure
group were CMV positive in the donor and/or recipi-
ent, this would actually be expected to decrease the
survival difference between groups. The small number
of patients in the high Bu exposure group precluded
the construction of a multivariable Cox proportional
hazards model simultaneously accounting for poten-
tial confounding variables. Addition of low-dose TBI
(400 cGy) did not alter the hazard ratio associatedwith high Bu AUC in our analysis, and was equally
represented in both groups. This is consistent with
our previous studies showing that addition of TBI
does not increase NRM in AML, and that the NRM
in early leukemia with this combination is below 5%
[30,31].
This regimen is designed to avoid toxicities of Cy,
including potentially fatal hepatic VOD. In a small
study using daily i.v. Bu with Cy, 2 of 5 patients
with a Bu AUC .6000 mM$min developed severe
VOD, and both eventually died; in another study by
Fernandez et al [32,33], 6 patients were given i.v. Bu
3.2 mg/kg daily with Cy; 1 patient developed VOD.
Following once-daily i.v. Bu with Flu, both we and
de Lima et al [20,22] have reported common eleva-
tions in bilirubin and liver enzymes but a very low
incidence of VOD (0 of 70 and 2 of 96 patients, re-
spectively). As opposed to i.v. Bu, oral Bu dosing
involves a hepatic first pass effect. Metabolites of Cy
itself likely contribute to VOD occurring after the
Bu/Cy regimen, an effect that may be avoided with flu-
darabine [34].
Our data provide no evidence that a higher Bu
exposure.6000 mM$min provides protection in terms
of lower relapse to compensate for increased toxicity.
It is difficult to comment on the relapse rate in this set-
ting, as this study involves a heterogeneous population
of patients with a variety of malignancies at different
stages of disease. However, the presence of high-risk
disease pretransplant was not found to impact the haz-
ard ratio for high busulfan exposure. Further study of
these findings among larger group of patients within
specific diagnosis categories is warranted.
In oral Bu dosing, TDM is associated with a rela-
tively low frequency of VOD and improved engraft-
ment [35,36]. Deeg et al [37] have given targeted oral
Bu 4 times daily (PK-guided dose adjustment to 600-
900 ng/mL, equivalent to AUC of approximately
900-1350 mM$min) with Cy for elderly MDS patients
and found favorable rates of OS, NRM, and relapse
compared to transplantation with other regimens. In-
dividualized dose adjustment of 4-times daily i.v. Bu
targeting an AUC of 1150 mmol/L/min per dose has
been well tolerated in children with Cy and thiotepa
with low rates of VOD [38].
This study suggests that Bu once-daily dosing
given with Flu for an AUC.6000 mM$min may be as-
sociated with increased NRM and worse OS. These
data are consistent with findings in other studies using
different dosing regimens, and support the role of
TDM with once-daily i.v. Bu. Further study with
larger patient numbers is required to establish whether
patient outcomes are improved with TDM.The devel-
opment of reliable test dose assays or real-time Bu dose
adjustment will aid in targeting Bu exposure into the
therapeutic range, and may provide a useful tool to
minimize Bu toxicity and NRM [39].
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